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ABSTRACT: Cyclic peptides containing tryptophan (W) and arginine (R) residues, [WR]5, [WR]6, [WR]7, [WR]8, and
[WR]9, were synthesized through Fmoc solid-phase chemistry to compare their molecular transporter eﬃciency. The in vitro
cytotoxicity of the peptides was evaluated using human leukemia carcinoma cell line (CCRF-CEM) and normal kidney cell line
(LLC-PK1). [WR]6, [WR]7, [WR]8, and [WR]9 were not signiﬁcantly cytotoxic to LLC-PK1cells at a concentration of 10 μM
after 3 h incubation. Among all the peptides, [WR]9 was found to be a more eﬃcient transporter than [WR]5, [WR]6, [WR]7,
and [WR]8 in CCRF-CEM cells for delivery of a cell-impermeable ﬂuorescence-labeled negatively charged phosphopeptide (F′-
GpYEEI). [WR]9 (10 μM) improved the cellular uptake of F′-GpYEEI (2 μM) by 20-fold. The cellular uptake of a ﬂuorescent
conjugate of [WR]9, F′-[W9R8K], was increased in a concentration- and time-dependent pattern in CCRF-CEM cells. The
uptake of F′-[W9R8K] was slightly reduced in CCRF-CEM cells in the presence of diﬀerent endocytic inhibitors, such as
nystatin, 5-(N-ethyl-N-isopropyl)amiloride, chlorpromazine, chloroquine, and methyl β-cyclodextrin. Furthermore, the uptake
of F′-[W9R8K] was shown to be temperature-dependent and slightly adenosine 5′-triphosphate-dependent. The intracellular/
cellular localization (in the nucleus and cytoplasm) of F′-[W9R8K] was conﬁrmed by ﬂuorescent microscopy in CCRF-CEM
cells. These studies suggest that large cyclic peptides containing arginine and tryptophan can be used as a molecular transporter
of speciﬁc compounds.
■ INTRODUCTION
The properties of the cell membrane create a barrier for the
eﬃcient cellular delivery of therapeutics. The cell membrane
contains phospholipids, which are negatively charged and
extremely hydrophobic. The phospholipids have been shown
to obstruct the transportation of negatively charged or water-
insoluble molecules. For example, phosphopeptides are cell-
impermeable compounds that are used as probes for studying
phosphoprotein−protein interactions.1−3 Phosphopeptides
consist of negatively charged phosphate groups that create an
obstacle for them to enter the negatively charged phospholi-
pids that make up the cell membrane of cells. Furthermore, a
number of anticancer and anti-human immunodeﬁciency virus
(HIV) agents have limited cellular uptake and/or a more
eﬃcient uptake is required for improving their biological
properties. Thus, the development of cellular delivery systems
for enhancing the delivery of cell-impermeable compounds,
such as phosphopeptides, and/or improving the delivery of
other biologically important compounds is urgently needed.
Cell-penetrating peptides (CPPs) have been introduced as a
drug delivery system for various applications.4−6 CPPs have
been shown to facilitate drug transport across the cell
membrane and increase the cellular uptake of the drug.
Other commonly used drug delivery systems include liposomes
and micelles. Encapsulating the drug in a liposome has
demonstrated to increase the eﬃciency of drug delivery and
prevent damage to the normal tissue. However, a previous
study has shown that liposomes still cause drug leakage,7
especially for highly hydrophilic drugs such as doxorubicin
(Dox) that is one of the most widely administered drugs for
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the treatment of cancer.8 Cancer cells can develop resistance to
certain types of anticancer drugs, such as Dox. Furthermore,
the high dose of the drug has been shown to cause irreversible
damage to the cardiac muscle.9 Thus, the advancement of
eﬃcient and safe vehicles to enhance the targeted delivery of
drugs to speciﬁc cells needs further studies.
There are many ways that the cellular uptake of CPPs may
occur. The most common ways include direct penetration and
endocytosis. Direct penetration may include inverted micelle
formation and pore formation. The endocytotic pathway
involves several pathways, such as macropinocytosis, phag-
ocytosis, endocytosis-independent of clathrin, or endocytosis-
dependent on the coat proteins clathrin or caveolin.10,11 The
CPPs that enter through an endosomal pathway may be
degraded by enzymes or have an inadequate amount of drug
released in the cytoplasm or nucleus. The best strategy to
overcome this limitation is to create a compound that will
bypass the endosomal pathway or enhance the rate of escape
from the endosome.12
We have previously reported the application of cyclic
peptide CPPs containing arginine (R) and tryptophan (W)
residues for delivery of diﬀerent cargo molecules. The data
conﬁrmed that cyclic peptides containing alternating trypto-
phan and arginine residues, [WR]4 and [WR]5, improved the
cellular uptake of compounds, such as anti-HIV drugs, Dox,
phosphopeptides, and siRNA or generated peptide nanostruc-
tures.13−21 Studies also showed that the amino acid sequences
in this peptide were oriented in such a way to allow the peptide
to cross the cell membrane easily without causing cytotoxicity
in the cell.9 Cyclic peptides were more rigid and expected to be
more stable toward proteolytic degradation. The cyclic nature
of the peptides provided higher stability versus the linear
counterparts and more eﬃcient cell penetration. We also
showed that the cellular uptake of [WR]4 and [WR]5 is
independent of the endocytotic pathway.13 We have also
reported that [WR]5 and [WR]5-capped gold nanoparticles
improved the cellular delivery of siRNA in HeLa cells by 2-
and 3.8-fold, respectively.16
In continuation of our eﬀorts to develop structure−cellular
uptake relationship for cyclic peptides containing W and R
residues, herein we synthesized and evaluated amphiphilic
cyclic CPPs composed of increasing numbers of W and R
residues, compared their eﬃciency with [WR]5 in improving
the cellular uptake of cell-impermeable compounds, estab-
lished structure−molecular transporter eﬃciency relationship,
and evaluated the mechanism of cellular uptake.
Figure 1. Chemical structures of synthesized cyclic peptides.
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Thus, ﬁve cyclic peptides, [WR]5, [WR]6, [WR]7, [WR]8,
and [WR]9, were synthesized containing alternate tryptophan
and arginine residues (Figure 1). The studies allowed us to
determine if there was any eﬀect on the molecular transporter
eﬃciency of the cyclic peptide by increasing the number of
hydrophobic and positively charged residues. Cytotoxicity of
the cyclic peptides was determined to ﬁnd an appropriate
noncytotoxic concentration for cellular uptake studies. Using
leukemia cancer (CCRF-CEM) cells, the cellular uptake
studies were evaluated to measure the uptake of ﬂuores-
cence-labeled compounds [e.g., phosphopeptide, stavudine
(d4T), emtricitabine (FTC), lamivudine (3TC)] in the
presence of the synthesized peptides [WR]5, [WR]6, [WR]7,
[WR]8, and [WR]9 compared to parent analogs in the absence
of the synthesized peptides. Structure−molecular transporter
eﬃciency relationship of the compounds was determined. A
ﬂuorescence-labeled derivative of the most eﬃcient peptide
was evaluated in the presence and absence of diﬀerent
endocytosis inhibitors, and the uptake was evaluated using
ﬂuorescence microscopy.
■ RESULTS AND DISCUSSION
Chemistry. Fmoc-solid phase peptide synthesis and
solution phase synthesis was used to synthesize all the peptides
[WR]x (x = 5−9) (Figure 1). The linear side-chain
protected peptides were assembled on H-Trp(Boc)-2-chloro-
trityl resin ﬁrst. After the cleavage of the peptides from the
resin in the presence of dichloromethane (DCM)/triﬂuor-
oethanol (TFE)/acetic acid (AcOH), the N- to C-terminal
cyclization was conducted in the presence of N,N′-
diisopropylcarbodiimide (DIC), 1-hydroxy-7-azabenzotriazole
(HOAt), and N,N-diisopropylethylamine (DIPEA). Final
deprotection was carried out, and the peptides were puriﬁed
using reverse-phase high-performance liquid chromatography
(HPLC) and characterized by using high-resolution matrix-
assisted laser desorption/ionization time-of-ﬂight (MALDI-
TOF) mass spectrometry. As a representative example, the
synthesis of [WR]9 is depicted in Scheme 1.
To synthesize the ﬂuorescence-labeled cyclic peptide
(Scheme 2), the peptide sequence was partially modiﬁed.
The N-terminal arginine was replaced with Fmoc-Lys(Boc)-
OH. Appropriately protected amino acids were assembled on
H-Trp(Boc)-2-chlorotrityl resin (0.3 mmol/g) according to
the solid-phase synthesis strategy described above. After the
cyclization and removal of all protecting groups, N-
hydroxysuccinimidyl ester (NHS) of 5(6)-carboxyﬂuorescein
(F′) was used for labeling the peptide. [W9R8]K peptide and
5(6)-carboxyﬂuorescein N-hydroxysuccinimide ester
(FAMNHS) were coupled in the presence of DIPEA in
anhydrous N,N-dimethylformamide (DMF). The coupling
reaction was completed in overnight. The puriﬁcation was
conducted according to the described general method above
used for other cyclic peptides to yield F′-[W9R8K] (Scheme 2).
The syntheses of ﬂuorescence-labeled phosphopeptide F′-
GpYEEI, F′-d4T, F′-3TC, and F′-FTC have been previously
reported by us,15,22−24 where F′ is 5(6)-carboxyﬂuorescein.
In Vitro Cytotoxicity Assay of Peptides. To evaluate the
cytotoxicity of [WR]x (x = 5−9), cell viability assay was
employed in normal kidney LLC-PK1 cell line at the
experimental concentration of 25 μM (Figure 2). Dox (5
μM) was used as a positive control. The percentage of cell
survival demonstrated that the peptides [WR]5 and [WR]6 did
not show any signiﬁcant toxicity at this concentration, whereas
Dox was cytotoxic even at 5 μM. The cytotoxicity was
gradually increased as the number of tryptophan and arginine
increased in the cyclic peptides. For example, [WR]7 and
[WR]8 reduced cell proliferation at 25 μM by 21 and 23%,
respectively, after 24 h incubation. [WR]9 showed signiﬁcant
toxicity and reduced the cell proliferation at 25 μM by 55%.
[WR]7 and [WR]9 exhibited signiﬁcantly more cytotoxicity
after 72 h (Figure 2).
Further studies were required to ﬁnd a noncytotoxic
concentration for [WR]9. To evaluate the cytotoxicity of
[WR]9, cell viability assay was conducted in LLC-PK1 cell line
at the experimental concentration of 1, 5, and 10 μM. The
percentage of cell survival demonstrated that [WR]9 reduced
cell viability by 19−23% at 24 h at these concentrations,
whereas Dox was cytotoxic at 5 μM reducing the cell viability
by 79% (Figure 3). These studies showed that the toxicity of
[WR]9 precluded it from being used at a higher concentration
and suggested that this compound could be used alternatively
as an anticancer agent at higher concentrations.
To determine a noncytotoxic concentration for all of [WR]x
(x = 5−9), cell viability assay was conducted in LLC-PK1 cell
Scheme 1. Synthesis of [WR]9.
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line at the experimental concentration of 10 μM. Dox (5 μM)
was used as the positive control. The percentage of cell survival
demonstrated that all the peptides, including [WR]9, showed
less toxicity at this concentration (10 μM), whereas Dox was
signiﬁcantly cytotoxic even at 5 μM (Figure 4). Surprisingly,
the peptides were less cytotoxic after 72 h incubation (Figures
3 and 4).
After selecting a nontoxic concentration of peptides, a
viability assay was performed at 10 μM against human
leukemia CCRF-CEM carcinoma cell line after 3 h incubation
(Figure 5). [WR]9 showed reduced cell viability by 23%. The
cytotoxicity of peptides was also evaluated at a concentration
of 10 μM against LLC-PK1 after 3 h (Figure 5). [WR]9
reduced the cell viability by 10%. The data indicate that the
peptide was less toxic against kidney cells at 10 μM
concentration after 3 h incubation. Thus, this concentration
was used for performing cellular uptake studies.
Cellular Uptake Studies. Cellular Uptake of A Fluo-
rescence-Labeled Phosphopeptide in the Presence of the
Peptides. Flow cytometry studies were performed by
ﬂuorescence-activated cell sorter (FACS) using CCRF-CEM
to measure the uptake of ﬂuorescence-labeled phosphopeptide
(F′-GpYEEI, 2 μM) in the presence of [WR]5, [WR]6, [WR]7,
[WR]8, and [WR]9 (10 μM). Cells and ﬂuorescence-labeled
phosphopeptide alone were used as negative controls. After 3 h
incubation, CCRF-CEM cells were analyzed by ﬂow cytometry
(Figure 6). [WR]9 (10 μM) signiﬁcantly enhanced the cellular
uptake of F′-GpYEEI (2 μM) when compared with the other
cyclic peptides. On the basis of the results, the physical mixture
of F′-GpYEEI (2 μM) with [WR]9 (10 μM) signiﬁcantly
enhanced the cellular uptake by 20-fold when compared to F′-
GpYEEI (2 μM) alone, whereas the physical mixture of F′-
GpYEEI (2 μM) with [WR]5 enhanced the uptake by 4-fold.
On the basis of these data, [WR]9 was found to be more
eﬀective when compared with [WR]5 in improving the cellular
Scheme 2. Synthesis of F′-[W9R8K]
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uptake of the phosphopeptide, presumably because a higher
number of positive charges and the larger size of [WR]9
provide adequate interaction and encapsulation of a large
linear negatively charged phosphopeptide in comparison to
[WR]5. Thus, cyclic [WR]9 was found to be the most eﬀective
peptide as the molecular transporter of ﬂuorescence-labeled
phosphopeptide among the synthesized peptides. Thus, further
studies were performed with [WR]9.
Cellular Uptake Studies of Fluorescence-Labeled Drugs in
the Presence of [WR]9. Flow cytometry studies were
performed using CCRF-CEM cells to measure the uptake of
ﬂuorescence-labeled phosphopeptide F′-GpYEEI (1 μM) and
ﬂuorescence-labeled anti-HIV drugs, such as F′-d4T (1 μM),
F′-3TC (1 μM), and F′-FTC (1 μM), in the presence of
[WR]9 (10 μM). The data were based on the mean
ﬂuorescence signal for 10 000 cells collected (Figure 7).
The physical mixture of F′-3TC (1 μM) and F′-d4T (1 μM)
with [WR]9 (10 μM) signiﬁcantly enhanced the cellular uptake
of F′-3TC and F′-d4T by 2-fold, whereas the physical mixture
of F′-FTC with [WR]9 enhanced the uptake only by 1.75-
fold (Figure 7). The presence of [WR]9 (10 μM) signiﬁcantly
enhanced the cellular uptake of the phosphopeptide, F′-
GpYEEI (1 μM), by 4-fold, which is less than when the
phosphopeptide was used at a higher concentration (2 μM,
Figure 6). These data indicate that an appropriate ratio of 5 to
1 between [WR]9 and phosphopeptide is required for more
eﬃcient uptake. The presence of [WR]9 also showed enhanced
cellular uptake of the anti-HIV drugs but not as signiﬁcant as
the phosphopeptide and in comparison to [WR]5.
13 Thus, we
assume that the cyclic structure in [WR]9 is too large, and
residues in the peptide are far for adequate interaction and
encapsulation, to carry small molecule drugs, such as anti-HIV
drugs. However, [WR]9 showed to be signiﬁcantly more
eﬃcient in the delivery of a larger linear phosphopeptide in
comparison to [WR]5.
Cellular Uptake of F′-[W9R8K]. To conﬁrm the cellular
uptake of cyclic peptide [WR]9 that contains alternating
arginine and tryptophan residues, a ﬂuorescently labeled
conjugate of the peptide, F′-[W9R8K], was synthe-
sized (Scheme 2), and the cellular internalization was studied.
The synthesis of the ﬂuorescently labeled peptide was
accomplished by replacing one arginine unit with a lysine
residue during solid-phase peptide synthesis and attaching
carboxyﬂuorescein (F′) to the side chain of lysine in the
solution phase. The cellular uptake of the selected
ﬂuorescence-labeled cyclic peptide F′-[W9R8K] was observed
by measuring the ﬂuorescence in the treated cells in a
concentration- and time-dependent manner and in the
presence of endocytosis inhibitors.
Flow cytometry studies were performed in CCRF-CEM cells
to determine the uptake of F′-[W9R8K] in diﬀerent
concentrations. The cells were incubated with 5(6)-carboxy-
ﬂuorescein (FAM) (1, 5, and 10 μM) and F′-[W9R8K] (1, 5,
and 10 μM) for 5 min, 30 min, and 1 h and were analyzed by
ﬂow cytometry (Figure 8). While the cellular uptake of FAM
Figure 2. Cytotoxicity of cyclic peptides (25 μM) in LLC-PK1 (normal kidney cells) after 24 and 72 h incubation using MTS assay.
Figure 3. Cytotoxicity of [WR]9 (1, 5, and 10 μM) in LLC-PK1
(normal kidney cells) after 24 and 72 h incubation using MTS assay.
Figure 4. Cytotoxicity of cyclic peptides (10 μM) in LLC-PK1
(normal kidney cells) after 24 and 72 h incubation using MTS assay.
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Figure 5. Cytotoxicity of cyclic peptides (10 μM) in CCRF-CEM and LLC-PK1 after 3 h incubation using MTS assay.
Figure 6. Intracellular uptake of F′-GpYEEI (2 μM) by [WR]5, [WR]6, [WR]7, [WR]8, and [WR]9 (10 μM) after 3 h incubation in CCRF-CEM
cell line.
Figure 7. Intracellular uptake of anti-HIV drugs [F′-FTC (1 μM), F′-3TC (1 μM), and F′-d4T (1 μM)] and F′-GpYEEI (1 μM) with [WR]9 (10
μM) in CCRF-CEM cells after 3 h incubation.
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did not improve as the concentration increased, the cellular
uptake of F′-[W9R8K] was signiﬁcantly enhanced in a
concentration-dependent manner with the highest uptake at
10 μM. The cellular uptake of the peptide was also time-
dependent and was at its highest after 1 h. Thus, the cellular
uptake of the ﬂuorescently labeled peptide was found to be
concentration- and time-dependent. F′-[W9R8K] was not
signiﬁcantly cytotoxic at this concentration (10 μM) and
time periods.
Mechanistic Studies. To determine whether the cellular
uptake was endocytosis-dependent, the transport of ﬂuores-
cence-labeled peptide F′-[W9R8K] (10 μM) was examined in
the presence of endocytosis inhibitors (Figure 9). CCRF-CEM
cells were pre-incubated by various inhibitors, including
nystatin chloroquine, chlorpromazine, methyl-β-cyclodextrin,
and 5-(N-ethyl-N-isopropyl)amiloride (EIA) for 30 min. The
cells were then incubated with F′-[W9R8K] (10 μM) for 1 h.
The uptake of F′-[W9R8K] decreased in the presence of
chloroquine but was signiﬁcantly reduced in the presence of
methyl-β-cyclodextrin, chlorpromazine, EIA, and nystatin. This
suggests that the mechanism of uptake could be dependent on
clathrin-mediated or caveolae-mediated endocytosis and
phagocytosis. However, the inhibitors did not block the uptake
of cargo completely, suggesting that other pathways are also
involved in the delivery of F′-[W9R8K].
Adenosine 5′-triphosphate (ATP) depletion was used to
determine whether F′-[W9R8K] (10 μM) uptake is energy-
dependent. CCRF-CEM cells were pre-incubated with 0.5% of
75 mM sodium azide in opti-minimum Eagle’s essential
medium (MEM) for 30 min prior to the addition of the
compound, followed by 1 h incubation. Although the cellular
uptake of F′-[W9R8K] (10 μM) was reduced by 1.8-fold in the
presence of sodium azide, signiﬁcant intracellular uptake was
still observed, suggesting that the uptake is not signiﬁcantly
reduced by inducing ATP depletion (Figure 10). Thus,
diﬀerent mechanisms may contribute to the peptide’s cellular
Figure 8. Dose- and time-dependent cellular uptake of FAM (1, 5, 10 μM) and F′-[W9R8K] (1, 5, 10 μM) in CCRF cells, after 5 min, 30 min, and
1 h incubation. NT is no treatment.
Figure 9. Cellular uptake of F′-[W9R8K] (10 μM) in CCRF-CEM cells pre-incubated with endocytosis inhibitors (30 min) after 1 h incubation.
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uptake. The cellular uptake of the peptide decreased
signiﬁcantly by 5.6-fold when incubated at 4 °C (Figure 11),
suggesting that the uptake of F′-[W9R8K] is signiﬁcantly
aﬀected by temperature.
Fluorescence Microscopy. Fluorescence microscopy was
performed using CCRF-CEM cells to monitor the cellular
uptake of F′-[W9R8K]. Figure 12 shows intracellular/cellular
localization (in the nucleus and cytoplasm) of F′-[W9R8K]
(10 μM) in CCRF-CEM cells after 3 h incubation at 37 °C.
These data indicate that the peptide has a cell permeability
property and could be used in transporting appropriate cargo
molecules across the cellular membrane as described above.
However, the exact localization of the peptide needs further
investigation.
Fluorescence microscopy studies were conducted to
demonstrate the cellular uptake of F′-GpYEEI (2 μM) in the
presence and absence of [WR]9 (10 μM) (Figure 13). F′-
GpYEEI alone did not show any signiﬁcant uptake. However,
there was a signiﬁcant diﬀerence in the uptake of F′-GpYEEI in
the presence of [WR]9. These data conﬁrm that [WR]9 can act
as a molecular transporter of the negatively charged F′-
GpYEEI.
■ CONCLUSIONS
A number of cyclic amphipathic peptide-containing arginine
and tryptophan residues, namely [WR]5, [WR]6, [WR]7,
[WR]8, and [WR]9 were synthesized through Fmoc solid-
phase chemistry and compared for their eﬃciency in improving
the cellular uptake of cell-impermeable compounds and
establish a structure−molecular transporter eﬃciency relation-
ship. The synthesized peptides were found not to be
signiﬁcantly toxic to normal kidney cell line (LLC-PK1) at
10 μM after 3 h incubation when compared with CCRF-CEM
cell lines. Among all the synthesized peptides, [WR]9 (10 μM)
signiﬁcantly improved the uptake of F′-GpYEEI by approx-
imately 20-fold as compared to [WR]5 which showed 4-fold
uptake. The cellular uptake of ﬂuorescently labeled conjugate
F′-[W9R8K] was found to be time- and concentration-
dependent. The cellular uptake of ﬂuorescence-labeled
conjugates, F′-FTC, F′-3TC, and F′-d4T, was slightly
increased in CCRF-CEM cells, in the presence of [WR]9 as
compared to the drugs alone. However, [WR]9 showed to be
the most eﬃcient in improving the uptake of the phosphopep-
tide. The presence of diﬀerent endocytosis inhibitors reduced
the cellular uptake of F′-[W9R8K] in CCRF-CEM cells.
However, these inhibitors did not completely block the
uptake. Therefore, we can conclude the uptake of this peptide
is not completely dependent on endocytosis and other
mechanisms of entry are possible. Intracellular cellular
localization (in the nucleus and cytoplasm) of F′-[W9R8K]
after 3 h incubation at 37 °C was conﬁrmed by ﬂuorescence
microscopy in CCRF-CEM. These data suggest that increasing
the number of alternating positively charged arginine residues
and hydrophobic tryptophan residues in a cyclic peptide was
an optimal approach for generating compounds with eﬃcient
molecular transporter properties for large molecules, such as a
negatively charged phosphopeptide. The work advances the
scientiﬁc knowledge in the area of cyclic peptide-based delivery
systems for improving the cellular uptake of cell-impermeable
compounds.
Figure 10. Cellular uptake of F′-[W9R8K] (10 μM) in CCRF-CEM
cells pre-incubated with sodium azide (375 μM) for 1 h, followed by 1
h incubation.
Figure 11. Cellular uptake of F′-[W9R8K] (10 μM) in CCRF-CEM
cells pre-incubated at 4 °C for 30 min compared with CCRF-CEM
cells pre-incubated at 37 °C, followed by 1 h incubation.
Figure 12. Fluorescence microscopy images of F′-[W9R8K] (10 μM) after 3 h incubation in the CCRF-CEM cells.
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■ EXPERIMENTAL SECTION
Materials. All amino acids and resins were obtained from
AAPPTec. Other chemicals and reagents were purchased from
Sigma-Aldrich. The chemical structures of the ﬁnal products
were conﬁrmed by high-resolution MALDI-TOF, model # GT
0264 from Bruker Inc. Final compounds were puriﬁed by a
reversed-phase HPLC system from Shimadzu (LC-20AP)
using a gradient system of acetonitrile and water and a
reversed-phase preparative column (XBridge BEH130 Prep
C18). Fluorescence-labeled phosphopeptide (F′-GpYEEI) and
ﬂuorescence-labeled anti-HIV drugs [2′,3′-dideoxy-5-ﬂuoro-3′-
thiacytidine (FTC), 2′,3′-didehydro-2′,3′-dideoxythymidine
(d4T), and ﬂuorescence-labeled lamivudine (3TC)] were
prepared and characterized according to the previously
reported procedures.15,22−24 Human leukemia carcinoma cell
line (CCRF-CEM, ATCC no. CCL-119) and normal kidney
cell line (LLC-PK1, ATCC no. CRL-1392) were purchased
from American Type Culture Collection (ATCC).
Methods. General Cyclic Peptide Synthesis. Fmoc-Arg-
(Pbf)-OH and Fmoc-Trp(Boc)-OH were used as building
block amino acids in the peptide synthesis. First, the linear
protected peptides (W(Boc)R(Pbf))5, (W(Boc)R(Pbf))6, (W-
(Boc)R(Pbf))7, (W(Boc)R(Pbf))8, and (W(Boc)R(Pbf))9
were synthesized on H-Trp(Boc)-2-chlorotrityl resin in 0.30
mmol scale. The NH2-Trp(Boc)-2-chlorotrityl resin was
swelled in DMF under dry nitrogen for 30 min. The solvent
was ﬁltered. The Fmoc-protected amino acid was coupled to
the N-terminal in the presence of 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexaﬂuorophosphate (3 equiv),
DIPEA (6 equiv), and DMF mixing for 1 h under nitrogen
gas. The reaction solution was ﬁltered after the coupling
reaction completed. The resin was washed with 15 mL of DMF
for 5 min twice. Fmoc deprotection was performed using
piperidine in DMF (20% v/v, 2 × 15 min). The reaction
solution was ﬁltered oﬀ, and the resin was washed with DMF
(2 × 5 min). The followed amino acids were coupled using the
same protocol to assemble the complete linear protected
peptide on trityl resin. The N-terminal Fmoc group was
deprotected on the ﬁnal amino acid using piperidine in DMF
(20% v/v, 2 × 15 min). The resin was washed with DMF (2 ×
5 min) and methanol (15 mL, 5 min) and dried. The partially
protected peptides were cleaved from the resin support after
agitating the peptidyl resin with freshly prepared cleavage
cocktail, DCM/TFE/AcOH (35 mL:10 mL:5 mL), for 3 h.
The solvents were evaporated under vacuum using low
pressure after mixing with hexane (2 × 20 mL) and DCM
(2 ×15 mL) to remove the AcOH by forming an azeotropic
mixture. The crude material was obtained as a white solid.
MALDI analysis was used to conﬁrm the molecular weight
of the linear peptides after small cleavage of the peptide from
the resin. The protected linear peptides (0.3 mmol) were
cyclized in the presence of anhydrous DMF (100 mL),
anhydrous DCM (25 mL), DIC (1.21 mmol, 188 μL), HOAt
(0.9 mmol, 122.5 mg), and DIPEA. The cyclization reaction
occurred overnight under inert condition using nitrogen.
MALDI analysis was used to monitor the completion of
cyclization by checking the molecular weight of the cyclized
peptide. The solvents were removed under low pressure. A
freshly prepared cleavage cocktail, triﬂuoroacetic acid, anisole,
thioanisole, and 1,2-ethanedithiol (6300 μL:350 μL:210 μl:140
μL), was added to the mixture and stirred for 3 h. The cold
diethyl ether was added to precipitate the crude peptide and
was centrifuged to obtain solid peptide. MALDI analysis
conﬁrmed the molecular weight of the cyclic peptides without
any protecting groups. All the peptides were puriﬁed using
reversed-phase HPLC and lyophilized.
A ﬂuorescence-labeled derivative of the selected cyclic
peptide [WR]9 was synthesized as F′-[W9R8K], according to
the solid-phase synthesis strategy described above. The N-
terminal arginine was replaced with a lysine amino acid to
facilitate labeling with carboxyﬂuorescein (F′). After the
synthesis and puriﬁcation of the peptide [W9R8K], the
lyophilized powder of [W9R8K] peptide (4.5 mg, 1.47 μmol)
and FAMNHS (2.0 mg, 4,2μmol) was coupled using DIPEA
(5.12 μL, 29.4 μmol) in anhydrous DMF (1 mL). The
coupling reaction was completed overnight. The puriﬁcation
was conducted according to the described general method
above used for other cyclic peptides to yield F′-[W9R8K]
(Scheme 2). The peptides had a purity of >95% according to
the HPLC analysis.
[WR]6: MALDI-TOF (m/z) for C104H134N34O12: calcd
2051.0920; found 2051.9684 [M + H]+; [WR]7: MALDI-TOF
(m/z) for C119H154N42O14: calcd 2395.2630; found 2396.6132
[M + H]+; [WR]8: MALDI-TOF (m/z) for C136H176N48O16:
calcd 2737.4434; found 2738.1264 [M + H]+; [WR]9:
MALDI-TOF (m/z) for C153H198N54O18: calcd 3079.6238;
found 3080.3276 [M + H]+; F′-[W9R8K]: MALDI-TOF (m/z)
for C174H208N52O24: calcd 3409.6654; found 3411.1455 [M +
2H]+.
In Vitro Cytotoxicity Assay of Peptides. The in vitro
cytotoxicity of the peptides was evaluated using human
leukemia carcinoma cell line (CCRF-CEM, ATCC no. CCL-
119) and normal kidney cell line (LLC-PK1, ATCC no. CRL-
Figure 13. Cellular uptake of F′-GpYEEI (2 μM) in the presence and absence of [WR]9 (10 μM) in CCRF-CEM after 3 h incubation.
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1392) to determine the viability of the peptides according to
the previously reported procedure.10 CCRF-CEM cells were
seeded at 50 000 cells in 0.1 mL per well in 96-well plates.
LLC-PK1 cells were seeded at 5000 cells in 0.1 mL per well in
96-well plates. Both cell lines were seeded in medium RPMI-
1640 containing fetal bovine serum (10%), 24 h prior to the
experiment as per manufacture protocol.9 The compounds
were added to each well in triplicates at a concentration of 10
μM and incubated at 37 °C for 24 h in a humidiﬁed
atmosphere of 5% CO2. The compounds were tested at
diﬀerent concentrations (1−50 μM) and were added to each
well in triplicate and incubated for 3, 24, and 72 h at 37 °C in a
humidiﬁed atmosphere of 5% CO2. Cell viability was then
determined by measuring the ﬂuorescence intensity at 490 nm
using a SpectraMax M2 microplate spectrophotometer. The
percentage of cell survival was calculated as [(optical density
(OD) value of cells treated with the test mixture of
compounds) − (OD value of culture medium)]/[(OD value
of control cells) − (OD value of culture medium)] × 100%.
Cellular Uptake Studies. CCRF-CEM cells were used to
measure the cellular uptake of the F′-GpYEEI, ﬂuorescence-
labeled 3TC (F′-3TC), ﬂuorescence-labeled d4T (F′-d4T),
and ﬂuorescence-labeled FTC (F′-FTC). FACS analysis was
performed in order to measure the intracellular uptake of the
cargo and determine whether the presence of the peptide
aﬀects the uptake of F′-GpYEEI, F′-3TC, F′-d4T, and F′-FTC.
The ﬂuorescence intensity was measured in the presence and
absence of the synthesized peptides. The cells (5 × 105 cells
per well) were taken in 6-well plates in opti-MEM or serum-
free RPMI medium. F′-GpYEEI, F′-3TC, F′-d4T, and F′-FTC
at 2 μM were then added to the wells containing the
synthesized peptides [WR]x (x = 5−9) at 10 μM for 3 h of
incubation at 37 °C cells. F′-GpYEEI, F′-3TC, F′-d4T, and F′-
FTC alone (2 μM) were used as negative controls. After 3 h,
CCRF-CEM cells were centrifuged at 800 rpm, and the cells
were collected as precipitant. The cells were then washed with
PBS two times. Finally, the cells were resuspended in ﬂow
cytometry buﬀer and analyzed by ﬂow cytometry (FACSCa-
libur: Becton Dickinson) using FITC channel and CellQuest
software. The data presented were based on the mean
ﬂuorescence signal for 10 000 cells collected. All assays were
performed in triplicates. FACS analysis was performed to
measure the ﬂuorescence intensity intracellularly and to
determine whether the cyclic peptides were facilitating the
cargos to cross the membrane.
A similar study was performed by FACS using CCRF-CEM
cells with F′-3TC, F′-d4T, and F′-FTC at 5 μM with 3 h
incubation in the presence and absence of the synthesized
peptides. The cells (5 × 105 cells per well) were incubated with
the synthesized peptides (at 10 μM) for 3 h.
Mechanistic studies werecarried out in the presence of
endocytosis inhibitors, such as nystatin, chlorpromazine,
chloroquine, and methyl β-cyclodextrin, to determine whether
the uptake was endocytosis-dependent. CCRF-CEM cells were
seeded in 6-well plates (5 × 105 cells/well) in opti-MEM. The
cells were pre-incubated by various inhibitors including
nystatin (50 μg/mL), chloroquine (100 μM), chlorpromazine
(30 μM), methyl-β-cyclodextrin (2.5 mM), and EIA (50 μM)
for 30 min. The cells were then incubated with F′-[W9R8K]
(10 μM) and a similar concentration of inhibitors for 1 h. To
induce ATP depletion, the cells were pre-incubated with 0.5%
of 150 mM sodium azide in opti-MEM prior to the addition of
the compound followed by 1 h incubation. FACS was
performed as previously described.
Fluorescence Microscopy. CCRF-CEM cells (30 μL of 3
×106) were seeded with EMEM media overnight on a glass-
bottom culture dish. The cells were treated with F′-[W9R8K]
(10 μM) or [WR]9 (10 μM) + F′-GpYEEI (2 μM) in opti-
MEM and incubated for 3 h at 37 °C. After 3 h incubation,
cells were centrifuged at 800 rpm for 5 min. The cells were
then washed with 400 μL of PBS and centrifuged again. The
media was then added to the cells. The cells were then placed
on the cover slip and were detected by using a Keyence
ﬂuorescence microscope (BZ-X700. Keyence Corp. of
America, Itasca, IL).
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